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SUMMARY
Aims: To identify factors predicting improvement/stabilization on the Alzheimer’s Disease
Cooperative Study–Clinical Global Impression of Change (ADCS-CGIC) and investigate
whether early treatment responses can predict long-term outcomes, during a trial of
13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s
disease (AD). Methods: Logistic regression was used to relate Week 24 ADCS-CGIC score
to potential baseline predictors. Additional analyses based on receiver-operating character-
istic curves were performed using Week 8/16 ADCS-CGIC scores to predict response
(13.3 mg/24 h patch) at Week 24. ADCS-CGIC score of (1) 1–3 = “improvement,” (2)
1–4 = “improvement or no change”. Results: “Treatment” (13.3 mg/24 h patch) and
increased age were significant predictors of “improvement” (P = 0.01 and P = 0.003,
respectively), and “treatment” (P = 0.001), increased age (P = 0.002), and prior AD treat-
ment (P = 0.03) for “improvement or no change”. At Week 8 and 16, ADCS-CGIC scores of
4 and 5 were optimal thresholds in predicting “improvement,” and “improvement or no
change,” respectively, at Week 24. Conclusions: A significant therapeutic effect of high-
dose rivastigmine patch on ADCS-CGIC response was observed. The 13.3 mg/24 h patch
was identified as a predictor of “improvement” or “improvement or no change”. Patients
with minimal worsening/improvement/no change after treatment initiation may be more
likely to respond following long-term therapy.
Introduction
The 13.3 mg/24 h rivastigmine transdermal patch is approved in
the USA for the symptomatic treatment of mild-to-moderate and
severe Alzheimer’s disease (AD) [1]. Approval for the severe
indication was based on proven efficacy of the high-dose
13.3 mg/24 h rivastigmine patch in the ACTION (ACTivities of
daily living and cognitION) study [1,2].
The ACTION study was a 24-week, randomized, double-blind
comparative study of 13.3 mg/24 h versus 4.6 mg/24 h
rivastigmine patch in patients with severe AD (ClinicalTrials.gov
identifier: NCT00948766) [2,3]. In this study, significantly less
decline was observed with 13.3 mg/24 h versus 4.6 mg/24 h
rivastigmine patch on both co-primary endpoints, the change
from baseline at Week 24 on the Severe Impairment Battery
(SIB; P < 0.0001) and the Alzheimer’s Disease Cooperative
Study–Activities of Daily Living scale–Severe Impairment Version
(ADCS-ADL-SIV; P = 0.025) [2]. Significant between-group
differences at Week 24 were also observed on the Alzheimer’s
Disease Cooperative Study–Clinical Global Impression of Change
(ADCS-CGIC), a secondary measure of global function [2].
Despite the greater efficacy demonstrated with 13.3 mg/24 h
versus 4.6 mg/24 h rivastigmine patch, similar proportions of
patients in both treatment groups reported adverse events (AEs;
74.6% and 73.3%, respectively) [2].
Patients with severe AD are likely to experience continuous
functional and cognitive decline, regardless of whether or not they
are receiving treatment. Achieving short-term improvement,
longer-term stabilization or a slowed decline in one or more
clinically relevant symptom domains may therefore represent a
therapeutic benefit [4]. If clinically relevant factors predictive of a
response on the ADCS-CGIC (improvement or stabilization) can
be identified, this could guide clinicians’ decision-making when
managing patients with severe AD and encourage an individual-
ized approach to patient management.
In addition to identifying relevant patient characteristics
associated with a response, analysis of early treatment outcomes
can be used to predict whether a patient is likely to respond to
treatment [5]. This investigation can be enhanced through the
application of receiver-operating characteristic (ROC) curve
analysis [5]. ROC analysis examines all possible outcomes for a
predictive measure, with each outcome yielding an estimated sen-
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sitivity and specificity, which equates to the probability of a true
response or true nonresponse, respectively [5].
Here, we present additional analysis of the ADCS-CGIC data
collected during the ACTION study. The objectives of the current
analyses were 2-fold: first, to identify patient characteristics at
baseline that may predict a response (improvement or
stabilization) on the ADCS-CGIC; and second, to evaluate
whether global functional status (ADCS-CGIC score) early after
treatment initiation, and following a further 8 weeks of
treatment, can be used to predict subsequent clinical outcomes
with the 13.3 mg/24 h rivastigmine patch.
Materials and Methods
Study Design and Patients
Detailed methodology of the ACTION study has been published
previously [2,3]. Briefly, patients were male or female, at least
50 years of age, with probable AD (original 1984 National Insti-
tute of Neurological and Communicative Disorders and Stroke and
the AD and Related Disorders Association criteria) [6] and a Mini-
Mental State Examination (MMSE) [7] score of 3–12, inclusive.
Patients were excluded if they had received cholinesterase inhibi-
tors (ChEIs) and/or other approved treatments for AD during the
previous 2 weeks, with the exception of stable memantine if taken
for at least 3 months prior to screening. Eligible patients (N = 716)
were randomized in a 1:1 ratio to 13.3 mg/24 h or 4.6 mg/24 h
rivastigmine patch for 24 weeks. Patients randomized to 13.3 mg/
24 h patch followed an 8-week titration schedule (via 4.6 mg/
24 h and 9.5 mg/24 h patch doses) before being uptitrated to the
target dose. Patients randomized to 4.6 mg/24 h patch remained
at that dose throughout the 8-week titration. Target doses were
maintained for 16 weeks from the end of the titration period.
The ACTION study was conducted in accordance with
Good Clinical Practice and the ethical principles of the Declaration
of Helsinki [2]. All patients, or their legally authorized
representative, provided written informed consent prior to
participating [2].
Outcome Measures
The co-primary outcome measures in the ACTION study were the
change from baseline at Week 24 on the SIB [8] and the ADCS-
ADL-SIV [2,3,9]. The SIB was developed to evaluate cognitive
dysfunction in patients with severe AD [8]. The version of the SIB
used in this study evaluated 40 items, with a possible range of
scores from 0 to 100 [8,10]. The ADCS-ADL-SIV is a caregiver-
based activities of daily living (ADL) scale, composed of 19 items
(score range 0–54), designed to assess ability to perform basic and
instrumental ADL in patients with severe AD [9].
The secondary efficacy measures included the ADCS-CGIC
score at Week 24 [2,3,11]. The ADCS-CGIC is a 7-point clinical
change scale [11]. Each patient is assigned a score, derived based
on the clinician’s perception of the patient’s change in global
clinical status over time, where 1 = “marked improvement,”
2 = “moderate improvement,” 3 = “minimal improvement,”
4 = “no change,” 5 = “minimal worsening,” 6 = “moderate wors-
ening,” and 7 = “marked worsening” [11].
These post hoc analyses of response were conducted by applying
definitions for “improvement” and “improvement or no change,”
stated in the original analysis plan, to the ADCS-CGIC scale. A
score of 1–3 on the ADCS-CGIC at Week 24 was defined as
“improvement,” and a score of 1–4 at Week 24 was defined as
“improvement or no change.”
Statistical Analyses
Proportion of Responders
The proportion of patients showing a response (“improvement” or
“improvement or no change”) on the ADCS-CGIC with
13.3 mg/24 h or 4.6 mg/24 h patch was a preplanned analysis.
P-values comparing the proportion of patients in the two
treatment groups showing “improvement” and the proportion
showing “improvement or no change” were calculated using
Cochran–Mantel–Haenszel statistics, controlling for pooled center.
This analysis was based on the modified full analysis set
(MFAS), which included all randomized patients who received at
least one dose of study medication and had at least one postbaseline
measurement on the ADCS-CGIC. Missing values were imputed
using the last observation carried forward (LOCF) approach.
Predictors of “Improvement” and “Improvement or
No Change”
In the post hoc analysis, a logistic regression model was used to
relate potential baseline predictors (“treatment” [13.3 mg/24 h
vs. 4.6 mg/24 h rivastigmine patch], gender [male vs. female],
prior AD treatment [treatment na€ıve vs. previously treated], time
since first symptoms of AD, MMSE score, age, body mass index
[BMI], and concomitant memantine use) to the response on the
ADCS-CGIC scale at Week 24. P-values and 95% confidence
intervals (CI) associated with coefficients of predictors were calcu-
lated using Wald chi-square statistics. In addition, the effect on
response from interactions of treatment-by-prior AD treatment,
treatment-by-time since first symptom of AD, treatment-
by-MMSE score, treatment-by-age, treatment-by-BMI, and treat-
ment-by-concomitant memantine use was assessed in separate
logistic regression models in addition to their corresponding main
effects. These analyses were also based on the MFAS with missing
data imputed using the LOCF approach.
Predictive Value of Early Treatment Response
(ROC Analysis)
Prediction of response to high-dose rivastigmine patch at Week 24
was investigated through the application of ROC curve analyses
based on early treatment outcomes using the MFAS. ROC curves
were generated using Week 8 and Week 16 ADCS-CGIC scores to
predict response (“improvement” or “improvement or no
change”) to 13.3 mg/24 h rivastigmine patch at Week 24. To
enable the selection of an optimal threshold value for the ADCS-
CGIC at Week 8 and Week 16, Youden’s index [12], a function of
both specificity and sensitivity, was plotted for each ROC curve.
The maximum value of the Youden’s index was used to pick the
optimum predictor threshold.
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Results
Study Population
Overall, 356 patients were randomized to 13.3 mg/24 h
rivastigmine patch, and 360 patients were randomized to
4.6 mg/24 h rivastigmine patch [2]. ADCS-CGIC data were avail-
able for 307 patients randomized to 13.3 mg/24 h rivastigmine
patch at Week 8, 312 patients at Week 16, and 313 patients at
Week 24. Of the 4.6 mg/24 h patch group, 309 patients provided
ADCS-CGIC data at Week 8, 314 at Week 16, and 315 patients at
Week 24. Baseline demographics and characteristics were similar
between treatment groups [2].
Proportion of Responders
At Week 24, 24.6% of patients (77/313) in the high-dose
(13.3 mg/24 h rivastigmine patch) group demonstrated
“improvement” on the ADCS-CGIC scale; this was significantly
higher compared with the 16.2% of patients (51/315)
demonstrating “improvement” in the low-dose (4.6 mg/24 h
rivastigmine patch) group (P = 0.01; Figure 1). Significantly, more
patients in the high-dose group demonstrated “improvement or no
change” compared with the low-dose group (58.8% [184/313]
and 45.4% [143/315], respectively; P = 0.001; Figure 1).
Predictors of “Improvement” and “Improvement
or No Change”
Treatment with high-dose 13.3 mg/24 h versus 4.6 mg/24 h
rivastigmine patch and age were significant predictors of
“improvement” at Week 24 (odds ratio [OR] = 1.65; 95% CI 1.10,
2.47; P = 0.01; and 1.04; 95% CI 1.01, 1.07; P = 0.003, respec-
tively; Table 1); these factors were also significant predictors of
“improvement or no change” at Week 24 (OR = 1.69; 95% CI
1.23, 2.34; P = 0.001 and 1.03 95% CI 1.01, 1.05; P = 0.002,
respectively, Table 1). The observed ORs suggest a 65%
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Figure 1 Proportion of patients showing “improvement,” and
“improvement or no change” on the ADCS-CGIC at Week 24 (MFAS-LOCF).
ADCS-CGIC, Alzheimer’s Disease Cooperative Study–Clinical Global
Impression of Change, MFAS-LOCF, modified full analysis set with a last
observation carried forward imputation.
Table 1 Predictors of “improvement” and “improvement or no change” from the logistic regression model (MFAS-LOCF)
Parameter Maximum likelihood estimate* Standard error Pr>ChiSq Odds ratio [95% CI]
“Improvement” at Week 24
“Treatment” (13.3 mg/24 h vs. 4.6 mg/24 h patch) 0.25 0.10 0.01 1.65 [1.10, 2.47]
Gender (male vs. female) 0.03 0.11 0.79 0.94 [0.62, 1.45]
Time since first AD symptoms 0.03 0.04 0.42 0.97 [0.89, 1.05]
Prior AD treatment (treatment na€ıve vs. previously treated) 0.03 0.18 0.86 1.07 [0.53, 2.15]
MMSE score 0.07 0.04 0.09 1.07 [0.99, 1.15]
Age 0.04 0.01 0.003 1.04 [1.01, 1.07]
BMI 0.04 0.02 0.10 1.04 [0.99, 1.08]
Concomitant memantine use 0.13 0.11 0.26 1.29 [0.83, 2.02]
“Improvement or no change” at Week 24
“Treatment” (13.3 mg/24 h vs. 4.6 mg/24 h patch) 0.26 0.08 0.001 1.69 [1.23, 2.34]
Gender (male vs. female) 0.09 0.09 0.30 0.83 [0.59, 1.18]
Time since first AD symptoms 0.01 0.03 0.73 1.01 [0.95, 1.08]
Prior AD treatment (treatment na€ıve vs. previously treated) 0.37 0.17 0.03 2.09 [1.08, 4.03]
MMSE score 0.03 0.03 0.30 1.03 [0.97, 1.09]
Age 0.03 0.01 0.002 1.03 [1.01, 1.05]
BMI 0.02 0.02 0.21 1.02 [0.99, 1.06]
Concomitant memantine use 0.07 0.09 0.42 1.16 [0.81, 1.67]
AD, Alzheimer’s disease; ADCS-CGIC, Alzheimer’s Disease Cooperative Study–Clinical Global Impression of Change; BMI, body mass index; CI, confi-
dence interval; MFAS-LOCF, modified full analysis set with a last observation carried forward imputation; MMSE, Mini-Mental State Examination. *A
positive maximum likelihood estimate indicates increased odds of “improvement” or “improvement or no change” when increasing the value of the
covariate or when in the given category. A negative estimate indicates a reduced odds of “improvement” or “improvement or no change.” “Improve-
ment” is defined as a Week 24 ADCS-CGIC score of 1–3, and “improvement or no change” as a Week 24 ADCS-CGIC score of 1–4.
ª 2015 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 21 (2015) 513–519 515
M. R. Farlow et al. Response to Rivastigmine Patch in Severe AD
“improvement or no change” when treated with high-dose versus
low-dose rivastigmine patch.
Being treatment-na€ıve was a significant predictor of
“improvement or no change” (OR = 2.09; 95% CI 1.08, 4.03;
P = 0.03), but not “improvement” alone at Week 24 (Table 1).
Treatment na€ıve patients (who accounted for 9% of the patients
in the analysis) demonstrated an estimated 109% greater chance
of “improvement or no change” when compared with those who
had received previous therapies.
No other baseline factors (gender, time since the first symptoms
of AD, MMSE score, BMI, or concomitant memantine use) were
shown to predict a response on the ADCS-CGIC (“improvement”
or “improvement or no change”; Table 1).
Interaction effects of “treatment” (13.3 mg/24 h vs.
4.6 mg/24 h rivastigmine patch) with prior AD treatment, MMSE
score, time since first symptoms of AD, age, BMI, or concomitant
memantine use were not observed for either definition of
response.
Predictive Value of Early Treatment Response
An ADCS-CGIC score of 4 at Week 8, indicating “no change,” was
the optimal threshold predictor of “improvement” on the ADCS-
CGIC at Week 24, with a sensitivity of 0.91 and a specificity of
0.61 (Figure 2A). A synthesis of the analysis showed that 100% of
patients with an ADCS-CGIC score of 1–3 and 91% of patients
with a score of 4 at Week 8 demonstrated “improvement” at Week
24. Similarly, an ADCS-CGIC score of 4 at Week 16 was the
optimal threshold predictor of “improvement” at Week 24
(sensitivity, 0.89; specificity, 0.69; Figure 2B).
An ADCS-CGIC score of 5, indicating “minimal worsening,” at
Week 8 was the optimal threshold predictor of “improvement or
no change” on the ADCS-CGIC at Week 24, with a sensitivity of
0.58 and a specificity of 0.81 (Figure 3A). All (100%) patients
with an ADCS-CGIC score of 1–3, 93% of patients with a score of
4, and 58% of patients with a score of 5 at Week 8 demonstrated
“improvement or no change” at Week 24. When using Week 16
data for the ROC analysis, a score of 5 was also the optimal thresh-
old predictor of “improvement or no change” at Week 24
(sensitivity, 0.67; specificity, 0.79; Figure 3B).
Discussion
One of the key objectives of this retrospective analysis was to
investigate whether certain baseline patient characteristics,
specifically rivastigmine patch treatment, gender, time since
manifestation of first AD symptoms, prior AD treatment, MMSE
score, age, BMI, and concomitant memantine use, could be used
to predict improvement or stabilization on the ADCS-CGIC in
patients with severe AD. Logistic regression analyses demon-
strated that treatment with 13.3 mg/24 h rivastigmine patch and
increased age were significant predictors of “improvement” or
“improvement or no change” in the patient’s global function,
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Figure 2 Prediction of “improvement” on the
ADCS-CGIC at Week 24 based on (A) Week 8
and (B) Week 16 ADCS-CGIC scores (MFAS).
ADCS-CGIC, Alzheimer’s Disease Cooperative
Study–Clinical Global Impression of Change;
MFAS, modified full analysis set.
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These findings extend previously published analyses from the core
ACTION study, where 13.3 mg/24 h rivastigmine patch
demonstrated significantly greater efficacy at Week 24 on the total
SIB, ADCS-ADL-SIV, and ADCS-CGIC versus the 4.6 mg/24 h
patch dose [2].
In another recent analysis of data from the ACTION study,
younger age was identified as being a single factor that
predisposed patients to rivastigmine patch application site skin
reactions [13]. It is interesting to note that not only are older
patients more likely to respond to rivastigmine patch therapy, but
they are also more likely to tolerate therapy.
A previous subanalysis of the IDEAL (Investigation of transDer-
mal Exelon in ALzheimer’s disease) study in a population with
mild-to-moderate AD demonstrated that, on the ADCS-CGIC, the
greatest rivastigmine–placebo differences were observed in
patients with more severe AD, compared with milder disease
stages [14]. This prior observation suggests that the probability of
a treatment effect increases with advancing disease stage and
provides a rationale for maintaining patients with severe AD on
treatment [14]. In the current analysis of patients with severe AD,
baseline MMSE score was not found to be a significant predictor
of treatment response. The inclusion criteria for the IDEAL study
were an MMSE score of 10–20 (inclusive); therefore, patients with
more severe disease in this study had scores overlapping the
mildest patients included in the ACTION study. Whether MMSE
score is a predictor of improvement or stabilization in severe AD
over the long term is unknown.
In the current analysis, patients who were treatment na€ıve also
demonstrated a greater likelihood of “improvement or no change”
compared with those who had previously received treatment for
AD. The reason for this is unclear; however, it could be
hypothesized that patients may have discontinued previous treat-
ment for AD due to a perceived poor response. Although uncon-
firmed, deterioration following even temporary withdrawal of a
ChEI may reduce the ability of the cholinergic system to benefit
following reintroduction of therapy. Alternatively, due to the
exclusion criterion that patients were not permitted to have
received ChEI treatment during the 2 weeks prior to the baseline
visit, there may have been residual unseen therapeutic effects
(perhaps stabilization) in previously treated patients that reduced
the overall observed magnitude of the treatment effect when
reintroducing treatment. It should be noted, however, that treat-
ment-na€ıve patients accounted for only 9% of the patients in the
analysis, which would also have influenced findings. Perhaps
more importantly, pharmacological differences are known to exist
between the ChEIs [15]. Information on prior and concomitant
use of AD medications was collected in the ACTION study; as
such, it is, in theory, possible to investigate the individual effect of
each ChEI (donepezil, galantamine, and rivastigmine) on subse-
quent treatment response. However, there are multiple confound-
ing factors not limited to the number of medications received,
duration of washout, and in many cases incomplete data regarding
the treatment period that affect the ability to perform these



















































Figure 3 Prediction of “improvement or no
change” on the ADCS-CGIC at Week 24 based
on (A) Week 8 and (B) Week 16 ADCS-CGIC
scores (MFAS). ADCS-CGIC, Alzheimer’s
Disease Cooperative Study–Clinical Global
Impression of Change; MFAS, modified full
analysis set.
ª 2015 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 21 (2015) 513–519 517
M. R. Farlow et al. Response to Rivastigmine Patch in Severe AD
generated. Further studies would be needed to investigate
whether the observed findings in treatment-naϊve patients are
upheld regardless of prior ChEI treatment recieved; such studies
should include a larger pool of treatment-naϊve patients, where
possible.
A previous study applied multiple definitions of response to
identify baseline factors that may predict response to ChEI
treatment [16]. One definition incorporated a measure of global
function, the Clinician’s Interview-Based Impression of Change
(CIBIC) [16]. In this analysis, a lower baseline MMSE score and
faster pretreatment disease progression were significant predictors
of response, defined as a ≥2-point improvement on the MMSE
and CIBIC score of 1–3, after 2 months of treatment [16]. Faster
pretreatment disease progression remained a significant predictor
after 6 months of treatment, although no differences were
observed with regard to the MMSE score [16]. Supporting the
current analysis, neither gender nor duration of disease was found
to be a predictor of response on the CIBIC/MMSE [16].
To our knowledge, these were the first analyses to investigate
predictors of clinical outcomes in patients with severe AD. Post hoc
responder analyses have been performed on data from the
OPTIMA (OPtimizing Transdermal Exelon study In Mild-to-mod-
erate Alzheimer’s disease) study, a 48-week, double-blind
comparison of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine
patch in patients with mild-to-moderate AD who demonstrated
decline on the 9.5 mg/24 h patch dose [17,18]. In this analysis,
treatment with 13.3 mg/24 h rivastigmine patch and MMSE score
were significant predictors of improvement (≥4-point improve-
ment on the Alzheimer’s Disease Assessment Scale–cognitive
subscale and no change on the Alzheimer’s Disease Cooperative
Study–ADL scale) or no decline at Week 24 [18]. Treatment with
13.3 mg/24 h rivastigmine patch was also a significant predictor
of improvement, and MMSE score of no decline, at Week 48 [18].
The current findings suggest that as well as being a predictor of
response in patients with mild-to-moderate AD, treatment with
13.3 mg/24 h rivastigmine patch may also be relevant at severe
disease stages.
Gender was found to be a significant predictor of
“improvement” at Week 48, but not Week 24, in the OPTIMA
study [18]. As noted above, in the current analysis, neither
gender, time since the first symptoms of AD, BMI, nor concomi-
tant memantine use was shown to predict “improvement” or
“improvement or no change” on the ADCS-CGIC at Week 24.
The longer duration of the OPTIMA study compared with the
ACTION study provides evidence that baseline characteristics
could also be used to predict long-term patient outcomes; how-
ever, whether this translates to a patient population with severe
disease requires further investigation.
A further objective of the current analysis was to use ROC
curves to evaluate whether global functional status early after
treatment initiation can predict clinical outcomes. These analyses
suggest that patients with minimal worsening, no change, or
improvement on the ADCS-CGIC at Week 8 may benefit from
long-term treatment with 13.3 mg/24 h patch. Data from these
ROC analyses can help a physician to decide after 8 weeks of
treatment with 13.3 mg/24 h rivastigmine patch whether a
patient should continue on the same treatment until Week 24.
The findings at Week 8 were supported by those at Week 16. In
the ACTION study, at Week 8, patients were titrated from
9.5 mg/24 h to 13.3 mg/24 h patch. Therefore, as well as inform-
ing physicians on potential long-term outcomes following
treatment, these findings also support a rationale for uptitrating to
maximum tolerated doses, in order to achieve optimal therapeutic
outcomes.
Although understanding the factors predictive of improvement
or stabilization on the ADCS-CGIC and the potential for early
treatment responses to predict long-term outcomes may guide
physicians when managing patients with severe AD, these
findings should be interpreted with caution. These post hoc
analyses were intended to be hypothesis forming and should be
interpreted as such. The ADCS-CGIC was a secondary efficacy
measure in the ACTION study, and the study was not powered to
identify predictors of response on this scale. In addition, analyses
based on a different definition of a clinical outcome, or analyses
based on other scales, may yield different findings. Additional
studies designed with analyses of this kind prospectively planned
would be required to confirm these potentially valuable
observations.
Although a therapeutic approach that leads to improvement or
stabilization of symptoms represents a clinical benefit, it is impor-
tant to remember that, in severe AD, decline in global function is
inevitable [19]. Whereas the ROC analyses considered patients
demonstrating “improvement” or “improvement or no change”
on the ADCS-CGIC, as “responders,” the OPTIMA and ACTION
studies have demonstrated significantly less decline on multiple
symptom domains with 13.3 mg/24 h patch versus an active
comparator [2,17]. This suggests that reduced deterioration may
also be considered a clinical benefit of treatment with rivastigmine
patch in patients with AD and again supports uptitration to the
highest tolerated treatment doses. With this in mind, the potential
for patient characteristics to influence treatment outcomes, the
importance of conveying realistic expectations of treatment, and
taking an individualized, adaptive approach to managing AD
cannot be overemphasized.
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